DINE-CD

A randomized, multicenter, comparative effectiveness trial of specific carbohydrate and Mediterranean diets to induce remission in patients with Crohn’s Disease.

This is a research study for patients with Crohn’s Disease who have evidence of inflammation. Participants will remain on the study and continue to receive the study investigational Mediterranean style diet or specific carbohydrate diet for the first 6 weeks. It is estimated that patients will participate for a minimum of approximately 4 months. During this time, participants will be evaluated by the study team at week 6 and at week 12.  

Vedolizumab-4006

An Open-Label, Phase 4 Study to Evaluate the Efficacy and Safety of Triple Combination Therapy with Vedolizumab IV, Adalimumab SC, and Oral Methotrexate in Early Treatment of Subjects with Crohn’s Disease Stratified at Higher Risk for Developing Complications (Takeda Vedolizumab-4006).

This is a phase 4 research study for patients with newly diagnosed with Crohn’s disease within the last 24 months, aged 18-80 years old. Participants will remain on the study and continue to receive the study investigational medication and until the study is completed unless they are Early Discontinued or voluntarily end participation. It is estimated that patients will participate for a minimum of approximately 2 years. During this time, participants will be evaluated by the study team every 2-4 weeks for up to 128 weeks. 

For more information or eligibility criteria, call our Research Hotline number at 612-870-5599, OR input the following information and we will follow up with you to discuss your interest:

ATTENTION: This form is not meant for transmitting medical, prescription or appointment information or to initiate direct communications with our health care providers. Those inquiries should be sent through the Patient Portal or you can contact us at (612) 871-1145. Web form submissions are monitored Monday through Friday during regular business hours. In the event of a medical emergency, please dial 911.